BlueRock Therapeutics Receives Permission from Health Canada for DA01 Trial in Parkinson s Disease
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., April 7, 2021 /PRNewswire/ BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced that Health Canada has given permission to initiate Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson s Disease (PD). This is the first trial in Canada to study pluripotent stem cell-derived dopaminergic neurons in patients with Parkinson s disease. We re excited to initiate this study with our expert collaborators at University Health Network in Toronto as we believe this trial could shift the treatment paradigm for PD patients in Canada and around the world, states Emile Nuwaysir, Ph.D., President and Chief Executive Officer of BlueRock. Our therapy is intended to replace the midbrain dopaminergic neurons lost in the
Bayer transforms pharma business through breakthrough innovation in healthcare 13:48 | 14/01/2021
Bayer has made exciting progress in transforming its pharmaceutical business with breakthrough innovations in healthcare that will significantly help patients suffering from conditions that are currently still difficult to treat.
Bayer highlighted its focus on cell, gene, and oncology pipelines during its virtual Pharma Media Day in Germany
The information was stressed at its virtual Pharma Media Day titled âTransforming Healthcare. Transforming Bayerâ in Germany. The event highlighted Bayer s focus on the cell, gene, and oncology pipelines.
âThe biomedical and technological revolution that is transforming healthcare at an unprecedented pace is taking place now. Our company is at the forefront of the wave of innovation in cell and gene therapy as well as digital health,â said Stefan Oelrich, member of the board of management at Ba
BlueRock Therapeutics in Collaboration with Memorial Sloan Kettering Cancer Center Receives IND Clearance for DA01 in Parkinson s Disease
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., Jan. 7, 2021 /PRNewswire/ BlueRock Therapeutics, a preclinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, in collaboration with Memorial Sloan Kettering Cancer Center (MSK), announced today that the U.S. Food and Drug Administration (FDA) has cleared their Investigational New Drug (IND) application to proceed with a Phase 1 (Ph1) study in patients with advanced Parkinson s disease (PD). This is the first trial in the United States to study pluripotent stem cell-derived dopaminergic neurons in patients with Parkinson s disease. Under the IND, BlueRock and MSK will execute a Ph1 clinical trial to evaluate the safety, tolerability and preliminary efficacy of DA01 in patients with PD.
Share this article
Share this article
ResearchAndMarkets.com s offering.
Cell Therapy Global Market Report 2020-30: COVID 19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global cell therapy market.
Major players in the cell therapy market are Fibrocell Science Inc., JCR Pharmaceuticals Co. Ltd., PHARMICELL Co. Ltd., Osiris Therapeutics Inc., MEDIPOST, Vericel Corporation, Anterogen Co. Ltd., Kolon TissueGene Inc., Stemedica Cell Technologies Inc. and AlloCure.
The global cell therapy market is expected to decline from $7.31 billion in 2019 to $7.2 billion in 2020 at a compound annual growth rate (CAGR) of -1.54%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupte
E-Mail
Skokie, IL - The ISSCR is bringing together successful biotech CEOs who have transformed scientific breakthroughs into thriving businesses that are improving human health into one program 7-8 January 2021.
VISION2030 comes at a pivotal moment in regenerative medicine and stem cell science as discovery, translation, and investment intersect.
Thursday, 7 January
STEMCELL Technologies Executive Interview
Interviewed by ISSCR Board Member Valentina Greco, Yale University School of Medicine, USA
STEMCELL Technologies mission is to advance the pursuit of scientific knowledge by supplying high quality, innovative reagents, tools, and services that enable life science research.
Surrozen Executive Interview
Claudia Janda, Princes Máxima Centrum, Netherlands l Surrozen Founder